Podcasts

Professor Ed Vital, Chair of the Lupus Forum, Associate Professor in Autoimmune Connective Tissue Diseases, and Honorary Consultant Rheumatologist at the University of Leeds in the UK, is joined by Professor Chris Edwards, a Consultant Rheumatologist and Honorary Chair of Clinical Rheumatology at University Hospital Southampton, UK. Together they discuss the key papers that were featured on the Lupus Forum from our November literature search.

Professor Ed Vital is joined by Professor Vibeke Strand to discuss the key papers that were featured on the Lupus Forum from our August and September literature searches.

Professor Ed Vital interviews Professors Victoria Werth and Richard Furie on their Phase 2 data on litifilimab in CLE and SLE. This discussion delves into the study design, results and what this means for clinical practice.

Professors Ed Vital and Eric Morand review the lupus literature from June and July. Join them as they discuss when to discontinue maintenance IST in lupus nephritis; biomarkers and key immune pathways, emerging therapies, and a comparison of anifrolumab and belimumab in SLE; as well as explaining what can be learnt from studies that don’t meet their endpoints.

Join Professors Ed Vital and Maria Dall'Era as they review the literature from April to May 2022, including disparities in the risk of end-organ manifestations in SLE in relation to race and ethnicity, the association between high Type I interferon activity and class III/IV LN, as well as anifrolumab efficacy and safety by Type I interferon gene signature, determinants of prolonged remission in SLE, impact of belimumb on organ damage, and the latest data for iberdomide and obinutuzumab.

Professor Joan Merrill discusses the results from the Phase 2 trial of iberdomide in SLE. Iberdomide is a cereblon modulator that promotes degradation of the transcription factors Ikaros and Aiolos, which affect leukocyte development and autoimmunity. In this Phase 2 trial, Iberdomide was evaluated for the treatment of SLE. Patients were randomly assigned in a 2:2:1:2 ratio to receive oral iberdomide at a dose of 0.45, 0.30, or 0.15 mg, or placebo once daily for 24 weeks. A higher percentage of patients receiving iberdomide 0.45 mg achieved SRI-4 response than those receiving placebo.